D M Pardoll

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes
    Z Lu
    Johns Hopkins University School of Medicine Oncology Center, Baltimore, Maryland 21231, USA
    J Exp Med 191:541-50. 2000
  2. pmc B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
    S Y Tseng
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Exp Med 193:839-46. 2001
  3. ncbi request reprint Cancer immunotherapy: breaking the barriers to harvest the crop
    Drew Pardoll
    Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Nat Med 10:887-92. 2004
  4. ncbi request reprint Does the immune system see tumors as foreign or self?
    Drew Pardoll
    Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Annu Rev Immunol 21:807-39. 2003
  5. ncbi request reprint Spinning molecular immunology into successful immunotherapy
    Drew M Pardoll
    Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Nat Rev Immunol 2:227-38. 2002
  6. ncbi request reprint Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells
    Xianzheng Zhou
    Division of Immunology and Hematppoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Hum Gene Ther 14:1089-105. 2003
  7. ncbi request reprint Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells
    Yan Cui
    Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Nat Med 9:952-8. 2003
  8. ncbi request reprint Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine
    E Y Chang
    Department of Pathology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA
    Int J Cancer 86:725-30. 2000
  9. ncbi request reprint Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras
    Leo Luznik
    Divisions of Hematopoiesis Immunology and Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 101:1645-52. 2003
  10. pmc Radiotherapy augments the immune response to prostate cancer in a time-dependent manner
    Timothy J Harris
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Prostate 68:1319-29. 2008

Detail Information

Publications69

  1. pmc CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes
    Z Lu
    Johns Hopkins University School of Medicine Oncology Center, Baltimore, Maryland 21231, USA
    J Exp Med 191:541-50. 2000
    ..Therefore, we conclude that CD4(+) help comprises at least three components: CD40-dependent DC sensitization, CD40-independent DC sensitization, and direct lymphokine-dependent CD4(+)-CD8(+) T cell communication...
  2. pmc B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
    S Y Tseng
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Exp Med 193:839-46. 2001
    ..These properties of B7-DC may account for some of the unique activity of DCs, such as their ability to initiate potent T helper cell type 1 responses...
  3. ncbi request reprint Cancer immunotherapy: breaking the barriers to harvest the crop
    Drew Pardoll
    Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Nat Med 10:887-92. 2004
    ..For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic...
  4. ncbi request reprint Does the immune system see tumors as foreign or self?
    Drew Pardoll
    Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Annu Rev Immunol 21:807-39. 2003
    ..Elucidation of these mechanisms provides new strategies for cancer immunotherapy...
  5. ncbi request reprint Spinning molecular immunology into successful immunotherapy
    Drew M Pardoll
    Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Nat Rev Immunol 2:227-38. 2002
    ..These strategies provide a blueprint for the development of successful immunotherapy over the next decade...
  6. ncbi request reprint Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells
    Xianzheng Zhou
    Division of Immunology and Hematppoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Hum Gene Ther 14:1089-105. 2003
    ..These results will have significant implications for the study of T-cell biology and for the improvement of clinical gene therapies of acquired immune deficiency syndrome (AIDS) and cancer...
  7. ncbi request reprint Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells
    Yan Cui
    Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Nat Med 9:952-8. 2003
    ..This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor...
  8. ncbi request reprint Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine
    E Y Chang
    Department of Pathology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA
    Int J Cancer 86:725-30. 2000
    ....
  9. ncbi request reprint Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras
    Leo Luznik
    Divisions of Hematopoiesis Immunology and Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 101:1645-52. 2003
    ....
  10. pmc Radiotherapy augments the immune response to prostate cancer in a time-dependent manner
    Timothy J Harris
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Prostate 68:1319-29. 2008
    ..To address this, we utilized a well-established, autochthonous murine model of prostate cancer to test whether RT could augment (or diminish) the CD4 T cell response to a tumor vaccine...
  11. ncbi request reprint Murine tumor antigens: is it worth the search?
    E M Jaffee
    Johns Hopkins Oncology Center, Baltimore, MD 21205 2196, USA
    Curr Opin Immunol 8:622-7. 1996
    ..Nonetheless, common features between murine and human tumor antigens are emerging, suggesting that these murine antigens will provide essential tools in the evaluation of antigen-based vaccines for the future treatment of cancer...
  12. ncbi request reprint Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation
    E M Jaffee
    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:145-56. 2001
    ..To determine its safety and ability to induce antitumor immune responses, we conducted a phase I trial in patients with surgically resected adenocarcinoma of the pancreas...
  13. pmc Cellular vaccine approaches
    Dung T Le
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, Bunting Blaustein Cancer Research Building, Room 407, Baltimore, MD 21231, USA
    Cancer J 16:304-10. 2010
    ....
  14. ncbi request reprint Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity
    Camie W Chan
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, CRB 440, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Nat Med 12:207-13. 2006
    ..By virtue of their capacity to kill target cells, followed by antigen presentation, IKDCs provide a link between innate and adaptive immunity...
  15. pmc Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model
    Satoshi Wada
    Department of Oncology, James Buchanan Brady Urological Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Cancer Res 69:4309-18. 2009
    ..Taken together, these data clarify the dose, timing, and mechanism of action by which immunomodulatory cyclophosphamide can be translated to a clinical setting in a combinatorial cancer treatment strategy...
  16. ncbi request reprint CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction
    Ching Tai Huang
    Oncology Center and Division of Comparative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Immunol 170:3945-53. 2003
    ..They also suggest that autoimmune pathology can result during the natural process of tolerance induction rather than requiring that tolerance be broken...
  17. pmc Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
    Charles G Drake
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Cell 7:239-49. 2005
    ..These results suggest that immunotherapy for prostate cancer may be most efficacious when administered after androgen ablation...
  18. pmc In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
    Tahiro Shin
    Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 201:1531-41. 2005
    ..These results highlight the contrasting in vivo roles of B7-DC and B7-H1 and indicate that B7-DC functions as a tuning molecule, selectively augmenting T helper 1 and CTL responses...
  19. pmc Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells
    Jean Kim
    Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Rm 3A65A, Baltimore, MD 21224, USA
    Am J Respir Cell Mol Biol 33:280-9. 2005
    ..Epithelial B7 homologs could play a role in regulation of lymphocytic activity at mucosal surfaces...
  20. pmc Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
    Fumihiko Tsushima
    Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 110:180-5. 2007
    ..Our results thus reveal previously unappreciated roles of B7-H1 and PD-1 interaction in the control of initiation and reversion of T-cell anergy...
  21. ncbi request reprint Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 66:1730-9. 2006
    ....
  22. ncbi request reprint Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation
    Katharine A Whartenby
    Sidney Kimmel Comprehensive Cancer Center at JHU, School of Medicine, Johns Hopkins University, Bunting Blaustein Cancer Research Building, Room 2M44, 1650 Orleans Street, Baltimore, MD 21231, USA
    Blood 100:3147-54. 2002
    ..These results suggest potential therapeutic approaches by manipulating lymphohematopoietic stem-progenitor cells to express FasL or other immune-modulating genes in the context of BMT...
  23. pmc Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease
    Katharine A Whartenby
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 102:16741-6. 2005
    ....
  24. ncbi request reprint Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 64:9105-14. 2004
    ....
  25. pmc Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells
    Joseph F Grosso
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 182:6659-69. 2009
    ....
  26. pmc Tc17 CD8 T cells: functional plasticity and subset diversity
    Hung Rong Yen
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 183:7161-8. 2009
    ..Tc17 also accumulated to a greater extent than did Tc1 cells, suggesting that adoptive transfer of CD8 T cells cultured in Tc17 conditions may have therapeutic potential for diseases in which IFN-gamma-producing cells are desired...
  27. pmc LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
    Joseph F Grosso
    Sidney Kimmel Comprehensive Cancer Center and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    J Clin Invest 117:3383-92. 2007
    ..Taken together, these data demonstrate a direct role for LAG-3 on CD8+ T cells and suggest that LAG-3 blockade may be a potential cancer treatment...
  28. ncbi request reprint Role of LAG-3 in regulatory T cells
    Ching Tai Huang
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Immunity 21:503-13. 2004
    ..We propose that LAG-3 marks regulatory T cell populations and contributes to their suppressor activity...
  29. ncbi request reprint Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes
    Kiyoshi Yoshimura
    Immunology and Hematopoiesis Division, Department of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 66:1096-104. 2006
    ..These findings show a general approach to focus systemic cancer immunotherapies to specific organs bearing tumor metastases by taking advantage of differential tropisms and the proinflammatory nature of microbes...
  30. ncbi request reprint In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions
    A J Adler
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Immunol 164:649-55. 2000
    ..Therefore, CD4+ T cell tolerance induction in vivo is not the result of an insufficient proliferative response elicited upon TCR engagement...
  31. pmc Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients
    T F Greten
    Department of Oncology and Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 364, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 95:7568-73. 1998
    ....
  32. ncbi request reprint Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity
    Timothy J Harris
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    J Immunol 179:4313-7. 2007
    ..Thus, STAT3 is a candidate target for T(H)17-dependent autoimmune disease immunotherapy that could selectively inhibit pathogenic immune pathways...
  33. pmc Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
    Monica V Goldberg
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Blood 110:186-92. 2007
    ..These findings demonstrate that, in addition to modulating effector functions in the periphery, B7-H1:PD-1 interactions regulate early T-cell-fate decisions...
  34. pmc Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis
    Sudarshan Anand
    Immunology Graduate Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Clin Invest 116:1045-51. 2006
    ..Our studies thus identify a what we believe to be a novel function of soluble LIGHT in vivo and offer a potential target for therapeutic interventions in hepatic inflammatory diseases...
  35. ncbi request reprint Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens
    Josef Mautner
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Int J Cancer 115:752-9. 2005
    ..These experiments show that a dual Th1/Th2, MHC class II-restricted T-helper-cell response against diverse shared tumor antigens has been elicited in this patient...
  36. ncbi request reprint Tumor immunology--towards a paradigm of reciprocal research
    Charles G Drake
    Johns Hopkins Department of Medical Oncology, Baltimore, MD 21231, USA
    Semin Cancer Biol 12:73-80. 2002
    ..The results of early clinical trials illustrate these points and underscore the critical importance of an interactive dialog between laboratory and clinical research efforts...
  37. doi request reprint Integrin alpha2 mediates selective metastasis to the liver
    Kiyoshi Yoshimura
    Department of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Blalock 685, Baltimore, MD 21287, USA
    Cancer Res 69:7320-8. 2009
    ..These findings define integrin alpha2 as a molecule conferring selective potential for formation of hepatic metastasis, as well as a possible target to prevent their formation...
  38. ncbi request reprint Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine
    Xianzheng Zhou
    Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer Res 65:1079-88. 2005
    ....
  39. ncbi request reprint Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases
    Ajay Jain
    Department of Surgery, Division of Immunology and Hematapoiesis, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Surg Oncol 10:810-20. 2003
    ..Granulocyte-macrophage colony-stimulating factor-transduced tumor cell vaccines are less effective against cancer as the interval between metastasis and the initial vaccination increases...
  40. doi request reprint Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    Julie R Brahmer
    Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 28:3167-75. 2010
    ..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...
  41. ncbi request reprint Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells
    Kiyoshi Yoshimura
    Department of Surgery and Immunology and Hematopoiesis Division, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 67:10058-66. 2007
    ..These results show the utility of LM in the treatment of hepatic metastases even in the absence of vaccine administration and further suggest that blockade of Treg cells and NK T cells will enhance antitumor activity...
  42. ncbi request reprint Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene
    C H Chen
    Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 8:128-38. 2001
    ..Our findings suggested that DNA vaccines may provide better tumor protection than vaccinia vaccines employing the same gene, which may have implications in the future design of antigen-specific cancer immunotherapy...
  43. ncbi request reprint Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology
    Dan A Laheru
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, Room 4M07, 1650 Orleans Street, Baltimore, MD 21231, USA
    Mol Cancer Ther 4:1645-52. 2005
    ..We outline here a paradigm for early-stage clinical development of immunotherapy combinations that use vaccines to drive tumor antigen-specific responses while simultaneously targeting immune regulatory pathways...
  44. pmc Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells
    Fan Pan
    Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Science 325:1142-6. 2009
    ..Silencing of Eos in Tregs abrogates their ability to suppress immune responses and endows them with partial effector function, thus demonstrating the critical role that Eos plays in Treg programming...
  45. pmc Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma
    Emilia Albesiano
    Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 70:6467-76. 2010
    ..These results show the importance of STAT3 activation in regulating the immunomodulatory mediators by human tumors and further validate STAT3 as a promising target for therapeutic intervention...
  46. ncbi request reprint Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2
    Maciej S Lesniak
    Department of Neurosurgery, The Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    J Neurooncol 64:155-60. 2003
    ..Our findings demonstrate that the use of a xenogenic cell line can provide a potent vehicle for the delivery of gene therapy and may therefore represent a new approach for brain tumor therapy...
  47. pmc Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells
    Derese Getnet
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    J Immunol 182:4675-85. 2009
    ..Interestingly, this Treg skewing was a property of even early-stage tumors, suggesting Treg induction as an important tolerance mechanism during tumor development...
  48. pmc High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection
    Alleluiah Rutebemberwa
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Immunol 181:8215-25. 2008
    ..These results support the idea that PD-1 expression on T cells specific for nonescaped epitopes contributes to viral persistence and suggest that PD-1 blockade may alter the outcome of HCV infection...
  49. ncbi request reprint Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin
    Fan Pan
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Nature 445:433-6. 2007
    ..Thus, Carabin is a negative feedback inhibitor of the calcineurin signalling pathway that also mediates crosstalk between calcineurin and Ras...
  50. ncbi request reprint Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats
    Richard E Clatterbuck
    Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Neurosurg 97:676-82. 2002
    ..In this report the authors confirm this hypothesis with mAbs directed against lymphocyte function-associated antigen-1 ([LFA-1] CD11a/CD18), the molecule on the surface of leukocytes that interacts with ICAM-1...
  51. pmc A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses
    Shaoguang Wu
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Nat Med 15:1016-22. 2009
    ..These results show a Stat3- and T(H)17-dependent pathway for inflammation-induced cancer by a common human commensal bacterium, providing new mechanistic insight into human colon carcinogenesis...
  52. pmc A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells
    Derese Getnet
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Mol Immunol 47:1595-600. 2010
    ..Taken together, these data suggest that Helios may play an important role in regulatory T cell function and support the concept that Helios may be a novel target to manipulate Treg activity in a clinical setting...
  53. pmc Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity
    Kimberly R Jordan
    University of Colorado Denver and Health Sciences Center, Denver, CO 80206, USA
    J Immunol 180:188-97. 2008
    ..Thus, the mechanism of Ag presentation induced by this vaccine is consistent with cross-priming by dendritic cells. This straightforward approach will facilitate future analyses of T cells elicited by peptide mimotopes...
  54. ncbi request reprint Building the bionic T cell
    Drew M Pardoll
    Nat Med 13:1411-3. 2007
  55. ncbi request reprint B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma
    Koichiro Matsumoto
    Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Biochem Biophys Res Commun 365:170-5. 2008
    ..These results suggest that B7-DC induced by IL-13 works as a feedback regulator by up-regulating IFN-gamma production during the effector phase of allergic asthma...
  56. ncbi request reprint Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells
    Suresh Radhakrishnan
    Department of Immunology, Mayo Medical and Graduate Schools, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Immunol 170:1830-8. 2003
    ..These findings imply that, in addition to known costimulatory roles, B7-DC can function as a receptor for signals delivered by cells expressing B7-DC ligands...
  57. ncbi request reprint Tumor reactive T cells get a boost
    Drew M Pardoll
    Nat Biotechnol 20:1207-8. 2002
  58. pmc Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells
    Loc T Nguyen
    Department of Immunology, Mayo Medical and Graduate Schools, Mayo Clinic, Rochester, MN 55905, USA
    J Exp Med 196:1393-8. 2002
    ..In addition to the established costimulatory and inhibitory functions associated with B7-DC, this molecule can also function as a conduit for extracellular signals to DCs modifying DC functions...
  59. ncbi request reprint Expression of programmed death 1 ligands by murine T cells and APC
    Tomohide Yamazaki
    Department of Immunology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    J Immunol 169:5538-45. 2002
    ..The inducible expression of PD-1 ligands on both T cells and APCs may suggest new paradigms of PD-1-mediated immune regulation...
  60. ncbi request reprint Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines
    Franck Housseau
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 98:57-62. 2002
    ....
  61. ncbi request reprint Differential binding properties of B7-H1 and B7-DC to programmed death-1
    Pornpan Youngnak
    Department of Molecular Immunology, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8549, Japan
    Biochem Biophys Res Commun 307:672-7. 2003
    ..Our results suggest that the differential binding properties of B7-H1 and B7-DC may be responsible for differential contributions of these two PD-1 ligands to immune responses...
  62. ncbi request reprint Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor
    Xiang yang Wang
    Department of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 51:311-9. 2002
    ..These observations demonstrate that manipulation of hsp110 expression in tumors, specifically when combined with GM-CSF, represents a potentially powerful approach to cancer vaccine formulation...
  63. ncbi request reprint Cutting edge: Expression of functional CD137 receptor by dendritic cells
    Ryan A Wilcox
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 168:4262-7. 2002
    ..Our findings implicate CD137 as an important receptor involved in the modulation of DC function...
  64. ncbi request reprint Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance
    Yiping Yang
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Immunol 5:508-15. 2004
    ..These results demonstrate that virus provides TLR signals required for bypassing regulatory T cell-mediated tolerance and emphasize the importance of persistent TLR signals for immunotherapy in the setting of established tolerance...
  65. pmc Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability
    Tsvetelina Pentcheva-Hoang
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:17765-70. 2007
    ..PD-1 and CD28 have similar kinetics of synaptic accumulation, suggesting that the process involves T cell receptor-triggered cytoskeletal reorganization followed by ligand binding...
  66. ncbi request reprint Immunostimulatory monoclonal antibodies for cancer therapy
    Ignacio Melero
    Centro de Investigación Médica Aplicada CIMA and Clínica Universitaria, Universidad de Navarra, Pamplona, Spain
    Nat Rev Cancer 7:95-106. 2007
    ..Importantly, mAbs of this type have now entered clinical trials with encouraging initial results...
  67. ncbi request reprint Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes
    Tim F Greten
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, FZ Oststadt, Raum 310, Pasteurallee 5, Germany
    J Immunol Methods 271:125-35. 2002
    ..These molecules bind antigen-specific T cells with high specificity and sensitivity, therefore, providing a valuable tool for detection as well as enrichment of antigen-specific T cells...
  68. ncbi request reprint Advances in gene therapy for malignant melanoma
    Maria G Sotomayor
    Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, USA
    Cancer Control 9:39-48. 2002
    ..Gene therapy targeted to the host's immune cells has been developed as an additional strategy to redirect immune responses against melanoma...
  69. ncbi request reprint Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors
    Maciej S Lesniak
    Division of Neurosurgery, The University of Chicago Hospitals, Chicago, IL 60637, USA
    J Neurooncol 70:23-8. 2004
    ..These results suggest that while high doses of dexamethasone can completely inhibit the immune response observed with IL-2, lower and more likely therapeutic doses of dexamethasone do not inhibit local IL-2 immunotherapy...